14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -1.042 1 day ( 0 % )
Last Price $3.16 -6.23 %
High/ Low $2.73 - $3.34 41.53%
Chg 7 Days 40.44 % $2.25 $3.16
Chg 30 Days -10.23 % $3.52 $3.16
Chg 12 mos -15.51 % $3.74 $3.16
Trend - 3 mos 7.94 % Width: 86.95 %
Trend - 12 mos -15.05 % Width: 319.79 %
Pred. range - 3 mos $2.32 - $4.34 -26.61 % - 37.21 %
Pred. range - 12 mos $0.782 - $3.28 -75.25 % - 3.92 %
Short MA avg 3 mos Sell Apr 29, 2024 - 4 days
Long MA avg 3 mos Buy Apr 30, 2024 - 3 days
Short/Long MA avg 3 mos Sell Apr 17, 2024 - 12 days
Short MA avg 12 mos Buy Apr 30, 2024 - 3 days
Long MA avg 12 mos Sell Apr 29, 2024 - 4 days
Short/Long MA avg 12 mos Buy Dec 28, 2023 - 87 days
Pivot Short Sell May 01, 2024 - 2 days
Bollinger Buy Sep 13, 2023 - 161 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About BioAtla, Inc.

BioAtla. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel... BCAB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT